See more : Amagasa Co., Ltd. (3070.T) Income Statement Analysis – Financial Results
Complete financial analysis of MannKind Corporation (MNKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MannKind Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Infrastructure Investment Limited (0600.HK) Income Statement Analysis – Financial Results
- DuoGenic StemCells corporation (7607.TWO) Income Statement Analysis – Financial Results
- Dermata Therapeutics, Inc. (DRMA) Income Statement Analysis – Financial Results
- National Bank of Greece S.A. (NBGIF) Income Statement Analysis – Financial Results
- The Ugar Sugar Works Limited (UGARSUGAR.BO) Income Statement Analysis – Financial Results
MannKind Corporation (MNKD)
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.75M | 174.76M | 0.00 | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Cost of Revenue | 62.77M | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M | 17.23M | 50.09M | 140.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 136.19M | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M | -5.48M | 124.67M | -140.41M | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Gross Profit Ratio | 68.45% | 42.37% | 48.49% | 62.17% | 55.62% | 26.49% | -46.68% | 71.34% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 31.28M | 19.72M | 12.31M | 6.25M | 6.90M | 8.74M | 14.12M | 14.92M | 29.67M | 100.24M | 109.72M | 101.52M | 99.96M | 112.28M | 156.33M | 250.44M | 256.84M | 191.80M | 95.35M | 59.27M | 45.61M | 42.72M | 19.76M | 20.54M |
| General & Administrative | 42.54M | 37.72M | 31.89M | 22.88M | 0.00 | 79.72M | 74.96M | 27.07M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 51.78M | 53.75M | 45.53M | 34.37M | 0.00 | 0.00 | 0.00 | 19.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 94.31M | 91.47M | 77.42M | 59.04M | 74.67M | 79.72M | 74.96M | 46.93M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 20.70M | 13.22M | 0.00 | 4.85M |
| Other Expenses | 1.92M | -102.00K | 339.00K | 23.00K | -926.00K | -437.00K | 13.00K | -597.00K | 1.37M | 1.68M | -635.00K | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.60M | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M | 88.86M | 59.58M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Cost & Expenses | 190.28M | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M | 106.09M | 109.67M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Interest Income | 6.15M | 2.51M | 112.00K | 167.00K | 997.00K | 501.00K | 293.00K | 85.00K | 18.00K | 9.00K | 8.00K | 7.00K | 18.00K | 40.00K | 70.00K | 5.13M | 17.78M | 0.00 | 3.71M | 932.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.16M | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M | 13.28M | 18.48M | 24.13M | 20.44M | 21.46M | 21.63M | 21.82M | 17.38M | 10.45M | 2.34M | 3.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.54M | 6.29M | 3.26M | 2.98M | 2.78M | 1.70M | 1.80M | 2.40M | 13.28M | 18.58M | 14.06M | 14.40M | 15.91M | 17.32M | 18.73M | 12.29M | 8.97M | 8.52M | 7.39M | 7.18M | 7.66M | 5.07M | 50.08M | -204.00K |
| EBITDA | 15.13M | -56.34M | -61.09M | -45.01M | -38.22M | -75.60M | -102.21M | 146.54M | -344.66M | -160.18M | -155.97M | -133.74M | -123.68M | -135.86M | -190.93M | -288.41M | -280.81M | -225.18M | -106.95M | -68.81M | -58.63M | -51.35M | 289.00K | -25.45M |
| EBITDA Ratio | 7.60% | -66.66% | -71.06% | -37.75% | -73.67% | -280.49% | -800.67% | 36.95% | 0.00% | 0.00% | 0.00% | -423,268.57% | -281,042.00% | -163,196.77% | 0.00% | -1,503,180.00% | -2,981,870.00% | -225,388.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.65% | -16,523.38% |
| Operating Income | 8.68M | -68.92M | -53.48M | -24.79M | -46.51M | -76.60M | -108.19M | 67.26M | -344.66M | -179.63M | -169.40M | -146.96M | -140.54M | -152.50M | -209.78M | -305.77M | -307.36M | -233.70M | -118.12M | -77.15M | -66.31M | -207.37M | -49.79M | -25.24M |
| Operating Income Ratio | 4.36% | -69.08% | -70.89% | -38.05% | -73.78% | -274.94% | -921.15% | 38.49% | 0.00% | 0.00% | 0.00% | -419,885.71% | -281,078.00% | -163,976.34% | 0.00% | -1,528,825.00% | -3,073,570.00% | -233,697.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,273.62% | -16,390.91% |
| Total Other Income/Expenses | -19.06M | -23.29M | -33.90M | -9.55M | -7.31M | -10.14M | -9.09M | 58.40M | -23.79M | -18.76M | -22.09M | -22.81M | -20.27M | -18.06M | -10.33M | 2.73M | 14.17M | 3.15M | 3.79M | 1.16M | 434.00K | 1.10M | 1.55M | 583.00K |
| Income Before Tax | -10.38M | -87.40M | -80.93M | -57.46M | -51.90M | -86.74M | -117.28M | 125.66M | -368.45M | -198.38M | -191.49M | -169.77M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.54M | -114.34M | -75.99M | -65.88M | -206.26M | -48.24M | -24.66M |
| Income Before Tax Ratio | -5.22% | -87.60% | -107.27% | -88.20% | -82.34% | -311.34% | -998.57% | 71.91% | 0.00% | 0.00% | 0.00% | -485,068.57% | -321,608.00% | -183,397.85% | 0.00% | -1,515,185.00% | -2,931,870.00% | -230,543.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,798.47% | -16,012.34% |
| Income Tax Expense | 1.56M | 24.77M | 10.87M | -218.00K | 7.83M | 240.00K | 51.00K | 13.72M | 12.22M | 3.55M | 6.77M | -408.00K | 5.91M | 738.00K | -8.28M | 2.00K | 3.00K | 5.00K | 1.00K | 1.00K | 1.00K | 2.00K | 2.00K | 2.00K |
| Net Income | -11.94M | -112.17M | -91.79M | -57.24M | -59.73M | -86.98M | -117.33M | 125.66M | -368.45M | -198.38M | -191.49M | -169.37M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.55M | -114.34M | -75.99M | -65.88M | -206.27M | -48.25M | -24.66M |
| Net Income Ratio | -6.00% | -112.43% | -121.67% | -87.87% | -94.75% | -312.20% | -999.00% | 71.91% | 0.00% | 0.00% | 0.00% | -483,902.86% | -321,608.00% | -183,397.85% | 0.00% | -1,515,195.00% | -2,931,900.00% | -230,548.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,799.08% | -16,013.64% |
| EPS | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| EPS Diluted | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| Weighted Avg Shares Out | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 103.83M | 92.05M | 81.16M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
| Weighted Avg Shares Out (Dil) | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 104.25M | 92.09M | 81.23M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Executive Vice President and Former Chief Financial Officer Chris Prentiss - Chief Financial Officer...
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.04 per share a year ago.
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 1Q 2024 Net income of $11M; Non-GAAP net income of $15M $304M of cash and cash equivalents and investments at March 31, 2024 In early April, repaid Midcap senior-secured debt and...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates...
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteers Enrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Source: https://incomestatements.info
Category: Stock Reports